Abstract
Background: The GSK3β has been associated to pathological functions in neurodegenerative diseases. This kinase is involved in hyperphosphorylation of microtubule-associated tau protein, leading to aggregation andformation of NFTs. It has clearly been shown that GSK3β is regulated at posttranslational level: phosphorylation at Tyr216 activates kinase, while phosphorylation at Ser9 is essential to inhibit its activity.
Objectives: At present, there are contradictory findings about the possibility that GSK3β may be regulated at gene level. Previous data showed overexpression of GSK3β mRNA in hypomethylating conditions, pointing out to the existence of epigenetic mechanisms responsible for GSK3β gene regulation. Analysis of human GSK3β promoter through bisulphite modification, both in neuroblastoma cells and in postmortem frontal cortex from AD patients (AD patients both at Braak stages I-II and at stages V-VI) , allowed us to characterize the methylation pattern of a putative CpG islands in human GSK3β 5’- flanking region. Results: The analysis evidenced overall hypomethylation of CpG and non-CpG cytosine residues both in cells and in human brain (AD patients and control subjects). We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects. Conclusions: These results point out that GSK3β hyperactivity, and then NFTs formation, could come into function at an early stage of the disease and then turn off at the last stages.Keywords: GSK3β, phosphorylation, late onset Alzheimer's disease, DNA methylation, GSK3β gene, Alzheimer patients, tau.
Current Alzheimer Research
Title:GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients
Volume: 14 Issue: 7
Author(s): Vincenzina Nicolia*, Viviana Ciraci, Rosaria A. Cavallaro, Isidre Ferrer, Sigfrido Scarpa and Andrea Fuso
Affiliation:
- Via A. Scarpa, 14, 00161-Roma,Italy
Keywords: GSK3β, phosphorylation, late onset Alzheimer's disease, DNA methylation, GSK3β gene, Alzheimer patients, tau.
Abstract: Background: The GSK3β has been associated to pathological functions in neurodegenerative diseases. This kinase is involved in hyperphosphorylation of microtubule-associated tau protein, leading to aggregation andformation of NFTs. It has clearly been shown that GSK3β is regulated at posttranslational level: phosphorylation at Tyr216 activates kinase, while phosphorylation at Ser9 is essential to inhibit its activity.
Objectives: At present, there are contradictory findings about the possibility that GSK3β may be regulated at gene level. Previous data showed overexpression of GSK3β mRNA in hypomethylating conditions, pointing out to the existence of epigenetic mechanisms responsible for GSK3β gene regulation. Analysis of human GSK3β promoter through bisulphite modification, both in neuroblastoma cells and in postmortem frontal cortex from AD patients (AD patients both at Braak stages I-II and at stages V-VI) , allowed us to characterize the methylation pattern of a putative CpG islands in human GSK3β 5’- flanking region. Results: The analysis evidenced overall hypomethylation of CpG and non-CpG cytosine residues both in cells and in human brain (AD patients and control subjects). We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects. Conclusions: These results point out that GSK3β hyperactivity, and then NFTs formation, could come into function at an early stage of the disease and then turn off at the last stages.Export Options
About this article
Cite this article as:
Nicolia Vincenzina*, Ciraci Viviana, Cavallaro A. Rosaria, Ferrer Isidre, Scarpa Sigfrido and Fuso Andrea, GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients, Current Alzheimer Research 2017; 14 (7) . https://dx.doi.org/10.2174/1567205014666170203153325
DOI https://dx.doi.org/10.2174/1567205014666170203153325 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology
Current Pharmaceutical Design The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology Inhibitors of Catechol-O-Methyltransferase
CNS & Neurological Disorders - Drug Targets Extra-telomeric Functions of Human Telomerase: Cancer, Mitochondria and Oxidative Stress
Current Pharmaceutical Design Structure and Mechanism of Action of Tau Aggregation Inhibitors
Current Alzheimer Research The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner
Anti-Cancer Agents in Medicinal Chemistry The Underestimated Role of Mechanical Stimuli in Brain Diseases and the Relate d In Vitro Models
Current Pharmaceutical Design The Effect of Lipopolymer Structure on the Transfection Efficiency of Hydrophobic Polyethylenimine-based Cationic Nanoliposomes
Current Nanoscience Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Current Pharmaceutical Design Promotion of Remyelination by Immunoglobulins: Implications for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Modulation of Endoplasmic Reticulum Stress: An Opportunity to Prevent Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews Nonsteroidal Anti-Inflammatory Drugs in Experimental Parkinsonian Models and Parkinsons Disease
Current Pharmaceutical Design Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry Neuroprotective Effect of β-secretase Inhibitory Peptide from Pacific Hake (Merluccius productus) Fish Protein Hydrolysate
Current Alzheimer Research Recent Developments in the Formulation of Nanoliposomal Delivery Systems
Current Nanomaterials Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Redox Sensitivity of Tyrosine Hydroxylase Activity and Expression in Dopaminergic Dysfunction
CNS & Neurological Disorders - Drug Targets Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry